Clinical Trials Logo

Clinical Trial Summary

Severe sepsis is a common condition with high mortality and morbidity. A previous meta-analysis has demonstrated the safety of glutamine supplementation with suggestion of mortality and morbidity benefits in critically ill patients. But there is lack of evidence to recommend the use of intravenous glutamine supplementation in this population group. A randomized controlled trial which is adequately powered will resolve this issue and can be included in future international nutrition guidelines for the critically ill. This pilot study is done prior to a proposed local multi-center study to investigate the effects of glutamine supplementation.


Clinical Trial Description

Objective

- To determine the effect of intravenous glutamine supplementation compared with placebo in critically ill patients with severe sepsis

- Primary outcome : 28 day mortality , Development of infectious complications

- Secondary outcomes

- Duration of mechanical ventilation

- Length of stay in ICU

- Length of stay in hospital

- 3 month survival status and resumption of baseline activities

- 6 month survival status and resumption of baseline activities

Study Design

- Single center, prospective, double blind, randomised controlled trial critically ill patients with severe sepsis

- Randomisation

- A centralised randomisation system at SCRI (Singapore Clinical Research institute)

- Allocation will be random and concealed, and will be blinded to everyone except the pharmacist at each site, who will be responsible for preparing and delivering them to the ICU in a blinded fashion.

- Intervention

- Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.

- IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.

- An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration.

- Cointerventions

- Nutritional support will be continued as per managing ICU team discretion.

- Management of severe sepsis will be continued as per managing ICU team discretion.

- Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.

- To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out.

Execution of study protocol

- The managing ICU team will be responsible in identifying patients that meet the inclusion and exclusion criteria and will inform the site research coordination

- The site research coordinator will be responsible for the following

- Obtaining consent from relatives of the patients

- Informing the site pharmacist about the recruited patients

- Follow study patients prospectively while in the ICU, hospital and post discharge at 3 and 6 months.

- Completing the case report from for each study participant

- Submitting case report forms, completed and interim reports, to coordinating statistical team

- Pharmacist

- Site pharmacist to liase with SCRI on randomised patients status (treatment vs. placebo)

- Prepare the intervention treatment and placebo

- Deliver the treatment and placebo to the respective patients.

- Nurses

- Responsible for administering the delivered medications

- Ensure and documenting compliance with administration, reasons for interruptions and documenting adverse reactions.

- Liasing with the site research coordinator daily regarding the above.

- Liasing with the site research coordinator on transfer, discharge or death of study participants ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03048994
Study type Interventional
Source Changi General Hospital
Contact
Status Completed
Phase N/A
Start date January 2011
Completion date June 2013

See also
  Status Clinical Trial Phase
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Completed NCT02539147 - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis N/A
Completed NCT01932814 - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful? N/A
Completed NCT01929772 - German Lactat Clearance in Severe Sepsis N/A
Completed NCT01449721 - Preemptive Resuscitation for Eradication of Septic Shock N/A
Active, not recruiting NCT01162109 - Zinc Therapy in Critical Illness Phase 1
Not yet recruiting NCT01211899 - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock N/A
Completed NCT00934011 - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections N/A
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00463645 - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients N/A
Completed NCT02361528 - GM-CSF to Decrease ICU Acquired Infections Phase 3
Completed NCT02734550 - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis N/A
Completed NCT02973243 - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Completed NCT01945983 - Early Use of Norepinephrine in Septic Shock Resuscitation N/A
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A